A malaria shot designed by vaccine maker Inovio Pharmaceuticals killed the disease in infected cells in animals while boosting immune responses, according to a new study.
In rats with tendon injuries that were treated with Pluristem Therapeutics' PLacental eXpanded (PLX) stem cell therapy, animals showed tendon healing at two and four weeks following injection, compared to saline-treated rats, according to the Haifa, Israel-based company.
Seattle BioMed has been awarded a $16.6 million grant from the National Institute of Allergy and Infectious Diseases that will allow it to perform what it believes will be the most comprehensive analysis to date of tuberculosis progression from latent infection to active disease.
The U.K. technology transfer organization MRC Technology and the nonprofit Parkinson's UK are partnering in the search for new therapeutic targets to slow, stop or reverse the progression of Parkinson's diseases.
Scientists may have unlocked a way to therapeutically correct genetic defects by using a new technique that targets and repairs defective genes.
A new stem cell treatment that combines neural stem cells with chemo-radiotherapy drugs could provide a better way to combat glioblastoma, the most common and lethal form of adult brain cancer.
U.K. researchers have discovered what role a newly identified team of proteins play in the process of cell division, and they say that harnessing these proteins could provide a new way to kill cancerous cells.
Biomedical researchers will now be able to apply for access to the whole genome data of an important cell line known as HeLa.
The University of Maryland, Baltimore, has forged new agreements with 5 life sciences companies in the Baltimore-Washington metropolitan region through its commercialization arm, University of Maryland Ventures.
Investigators from the Florida campus of the Scripps Research Institute have found that a compound that favors a certain biological pathway could provide scientists with a roadmap for future development of more effective drugs for addiction.
Scientists may soon be able to find novel ways to treat hepatitis C using a new laboratory model developed by researchers at the Icahn School of Medicine at Mount Sinai in New York.
A drug used since the 1960s to treat Type 2 diabetes appears to prolong both life and good health in middle-aged male mice. If further research supports the early results, the discovery could allow doctors to use the drug to stave off metabolic decline in humans as they grow older.
A compound derived from soybeans and other plants may have HIV-fighting properties, according to new research by scientists at George Mason University.
A team at the La Jolla, CA-based Sanford-Burnham Medical Research Institute has developed a compound called SMIP004 that causes a decrease in the number of androgen receptors--proteins located in prostate cancer cells that are activated by testosterone.
La Jolla Institute for Allergy and Immunology and Kyowa Hakko Kirin California, a subsidiary of Japanese pharmaceutical company Kyowa Hakko Kirin, have signed a 6-year drug discovery pact to develop therapies for a wide range of autoimmune diseases.
Targeting a key enzyme associated with heart disease could offer a new way to treat asthma, which affects billions of people worldwide, including 8.5% of the U.S. population.
A team of scientists is for the first time using a structure-based drug design approach to find new compounds designed to treat neurodegenerative disorders like Alzheimer's, Parkinson's and Lou Gehrig's diseases.
The latest outbreak of avian influenza in China earlier this year has spurred drug development interest in a vaccine to combat the deadly H7N9 strain, which health officials around the world have said has the potential to become a pandemic.
A monoclonal antibody developed by researchers at the National Institute of Allergy and Infectious Diseases could lay the groundwork for effective therapies against norovirus, which has in recent years infected school campuses, cruise ships, hospitals and nursing homes.
A DNA cancer vaccine developed by Blue Bell, PA-based Inovio Pharmaceuticals caused tumor cell death and increased the rate of survival in animal studies.